Table 3 Univariate and multivariate Cox regression analyses of LDH levels and OS of patients with advanced pancreatic cancer in the validation cohort.
Variable | Patients (n) | HR (95% CI) | p-value* |
|---|---|---|---|
Univariate analysis | |||
Sex (male vs. female) | 146 vs. 79 | 0.754 (0.554–1.026) | 0.073 |
Age (<60 vs. ≥60) | 88 vs. 137 | 1.014 (1.000–1.029) | 0.056 |
Stage (III vs. IV) | 44 vs. 181 | 1.616 (1.107–2.36) | 0.013 |
Location (head vs. body/tail) | 81 vs. 144 | 0.97 (0.718–1.309) | 0.84 |
CA19-9 (<1000 vs. ≥1000 IU/mL) | 116 vs. 109 | 1.931 (1.44–2.588) | <0.001 |
LDH (<185 vs. ≥185 IU/mL) | 147 vs. 78 | 0.694 (0.514–0.937) | 0.016 |
KPS (<90 vs. ≥90) | 137 vs. 88 | 1.052 (0.784–1.412) | 0.735 |
Metastasis (Intrahepatic vs. Extrahepatic) | 155 vs. 26 | 1.314 (0.846–2.039) | 0.224 |
Location of intrahepatic metastasis (Left/Rirht Lobe vs. Left&Right Lobe) | 23 vs. 132 | 1.072 (0.630–1.823) | 0.799 |
Albumin (<38.6 vs. ≥38.6 g/L) | 61 vs. 164 | 0.813 (0.590–1.120) | 0.205 |
PLR (<154 vs. ≥154) | 151 vs. 74 | 1.123 (0.826–1.527) | 0.458 |
NLR (<3.42 vs. ≥3.42) | 131 vs. 94 | 1.607 (1.197–2.159) | 0.002 |
LMR (<3.19 vs. ≥3.19) | 109 vs. 116 | 0.661 (0.493–0.886) | 0.006 |
Multivariate analysis | |||
Age (<60 vs. ≥60) | 88 vs. 137 | 0.934(0.694–1.258) | 0.655 |
Stage (III vs. IV) | 44 vs. 181 | 0.639 (0.431–0.947) | 0.026 |
CA19-9 (<1000 vs. ≥1000 IU/mL) | 116 vs. 109 | 0.626 (0.462–0.849) | 0.003 |
LDH (<185 vs. ≥185 IU/mL) | 147 vs. 78 | 0.747 (0.552–1.012) | 0.059 |
NLR (<3.42 vs. ≥3.42) | 131 vs. 94 | 0.777(0.534–1.131) | 0.188 |
LMR(<3.19 vs. ≥3.19) | 109 vs. 116 | 1.420(1.047–1.927) | 0.024 |
